GL1X · GenesisL1 explorer

Research workbench

Crystal structures of caspase-3 in complex with aza-peptide epoxide inhibitors.

Analyse Crystal structures of caspase-3 in complex with aza-peptide epoxide inhibitors. in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
2CNK
Type
protein
Length
252 residues
Chains
3
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Caspase-3 P17 subunit; Caspase-3 P12 subunit; Aza-peptide expoxide
EC
3.4.22.-
UniProt
P42574
Ligands
PHQ, MY2

Structure

x-ray diffraction · 3 distinct chains · 27% helix, 24% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ACaspase-3 P17 subunit (EC 3.4.22.-)protein14625% helix, 29% strandP42574
BCaspase-3 P12 subunitprotein10330% helix, 16% strandP42574
IAza-peptide expoxideprotein30% helix, 33% strand—

Ligands and binding sites

  • PHQ · benzyl chlorocarbonate · ligand · chains B, I
  • MY2 · {1-[(3S)-4-(benzyloxy)-3-hydroxy-4-oxobutanoyl]hydrazino}acetic acid · ligand · chains A, B, I

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Interfaces

3 interfaces between chains.

  • A–B · 2256 Ų buried · 32 hydrogen bonds · protein-protein
  • B–I · 329 Ų buried · 5 hydrogen bonds · protein-protein
  • A–I · 125 Ų buried · 1 hydrogen bond · protein-protein

Modifications

Observed in the structure: 3 covalent (covalent ligand).

Compared structures

  • 2CNK · Crystal structures of caspase-3 in complex with aza-peptide epoxide inhibitors. · the same entry in another collection · chain A against A, TM-score 1.00
  • P42574 · AlphaFold monomer V2.0 prediction for caspase-3 (P42574) · a predicted model of the same protein · chain A against A, TM-score 0.99

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.